Financials data is unavailable for this security.
View more
Year on year Abbott Laboratories had net income fall -51.32% from 13.40bn to 6.52bn despite a 5.67% increase in revenues from 41.95bn to 44.33bn.
| Gross margin | 56.65% |
|---|---|
| Net profit margin | 14.72% |
| Operating margin | 18.13% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in USDView more
In 2024, Abbott Laboratories increased its cash reserves by 10.44%, or 720.00m. The company earned 8.56bn from its operations for a Cash Flow Margin of 20.40%. In addition the company used 2.34bn on investing activities and also paid 5.40bn in financing cash flows.
| Cash flow per share | 5.30 |
|---|---|
| Price/Cash flow per share | 21.14 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in USDView more
SmartText is unavailable
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in USD
SmartText is unavailable
| Div yield(5 year avg) | 1.82% |
|---|---|
| Div growth rate (5 year) | 10.76% |
| Payout ratio (TTM) | 47.38% |
| EPS growth(5 years) | 8.18 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -51.41 |
More ▼
